Introduction {#sec1}
============

C--H bond functionalization via direct coupling strategy and installing a new C--C bond is considered as an attractive research area in organic synthesis.^[@ref1]^ Development of such methodologies not only facilitates the sustainable requirement of organic transformations but also found omnipresent applications in the synthesis of pharmaceuticals and complex natural products.^[@ref2]^ Over the years, the transition[-]{.ul}metal-catalyzed C--H bond functionalization via simple coupling reaction gained significant attention and several promising catalytic systems have been developed,^[@ref3]^ but the apparent drawbacks cannot be ignored anymore. This includes, high cost for the catalyst synthesis, severe toxicity of the metal salts, anhydrous conditions, and toxic solvents. In contrast, an eco-friendly coupling under metal-free condition is still scarce.^[@ref4]^

Natural products have been widely demonstrated to be the rich source of bioactive lead compounds according to their potential biological activity, good structural diversity, and compatibility with the environment and nontoxic potential.^[@ref5]^ Because of the versatile application in medicinal chemistry as well as in allied fields, the construction of natural products and their analogues with the direct coupling strategy without using any toxic metals has always been a keen research area for organic and medicinal chemists and in great demand.^[@cit5d]^

Additionally, there has been a paradigm shift from traditional organic chemistry to the one that assigns green chemistry values. Various simple metrics that include the principles of green chemistry such as atom economy, step economy, mass intensity, and E factors are essential parameters to the sustainable development of organic chemistry.^[@ref6]^ Moreover, the replacement or complete removal of hazardous solvents and catalysts in chemical transformations has required urgent attention by chemists toward the synthesis of active pharmaceutical ingredients (APIs). In this context, the organic reactions without hazardous solvents, metal catalysts, and additives can eliminate the contamination of APIs as well as it can curb the environmental pollution.^[@ref7]^ Therefore, considering the potential of the greener approach in organic synthesis, the development of new strategies via improving the atom economy of chemical processes and simple and efficient coupling under solvent- and catalyst-free approach for the construction of natural products and their analogues is a challenging task and are in great demand.

Schizocommunin is a natural product isolated from liquid culture medium of Schizophyllum commune strain and exhibits significant cytotoxic activity against murine lymphoma cells.^[@cit8a]^ The biological studies on schizocommunin and its synthetic analogues were less explored because of the lesser availability from natural resources. Chemically, the revised structure of schizocommunin **1** comprises 2-substituted quinazolinone connected by exomethylene-linked oxindole skeleton ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@cit8b]^ On the other hand, the functionalized quinazolinones are present in several bio-active natural products.^[@ref9]^ Amongst the quinazolinone class of bioactive compounds, the 2-substituted quinazolinone-based natural products such as schizocommunin,^[@cit8c]^ piriqualone,^[@cit10a]^ isaindigotone,^[@cit10b]^ CP-465022,^[@cit10c]^ ipsinesib,^[@cit10d]^ idelalisib,^[@cit10e]^ balaglitazone,^[@cit10f]^ asperlicin C,^[@cit10g]^ and benzomalvin A^[@cit10h]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) have attracted considerable interest because of their broad spectrum of biological activities. The syntheses of schizocommunin and its analogues via direct functionalization at the 2-position in quinazolinones were previously reported but these methodologies have apparent drawbacks, such as acid solvents, toxic catalysts, tedious reaction setup, recovery of intermediates, and purification process.^[@cit8b],[@cit8c]^ Therefore, there is an urgent need to develop a direct, metal free, environmentally benign route to access the schizocommunin analogues along with avoidance of the aforementioned drawbacks. Herein, as a continuation of our ongoing interest in the development of a "green and sustainable" novel catalytic methodology for biologically privileged heterocycles,^[@ref11]^ we wish to disclose an efficient, eco-friendly direct approach to access the schizocommunin analogues under catalyst- and solvent-free conditions. To the best of our knowledge, it is the first report of the environmentally benign scalable approach for the efficient construction of schizocommunin analogues under catalyst- and solvent-free simple conventional heating conditions.

![Schizocommunin and other 2-substituted quinazolinone-based natural products and bio-active molecules.](ao-2019-01514v_0001){#fig1}

Results and Discussion {#sec2}
======================

With an intention to obtain schizocommunin derivative **12a** under the environmentally benign approach, the precursor **10a** was first synthesized and screened the catalytic activity of different acid catalysts for the C--C bond formation. All the results are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. In an initial attempt, **10a** and **11a** were used as model substrates for the screening of various Brønsted as well as Lewis acids in eco-friendly solvents EtOH, ethylene glycol, and water. However, acids used in the reaction did not give promising results and the isolated yields of desired schizocommunin derivative **12a** were poor (\<30%, entries 1--8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Moving toward greener acid catalysts, that is boric acid, and greener solvents like ethylene glycol as well as water did not give promising results (entries 9--11, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). We further continued our screening under catalyst- and solvent-free conditions, but the result was not improved (entry 13, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). However, when we increased the temperature to 140 °C, surprisingly, we obtained the product **12a** in higher amounts (53%) compared to other previous conditions (entry 14, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Therefore, we further performed a set of the reaction under solvent- and catalyst-free conditions at elevated temperatures (entries 15--18, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). To our delight, on only increasing the reaction temperature and time, the better yield of desired product **12a** was obtained (yield = 93%, entry 16, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Further increasing or decreasing the reaction time diminishes the yield of **12a** (entries 17--18, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Therefore, the reaction of **10a** with **11a** at 180 °C under solvent- and catalyst-free conditions for 6 h was the optimized eco-friendly reaction condition for the synthesis of schizocommunin derivative **12a** (entry 16, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). It is important to note that purity of the product **12a** was high enough for the direct spectroscopic analysis without any further purification. In general, reaction temperature is crucial to directly influence the molten condition and for the uniformity of the reactants under solvent-free conditions. Thus, the solvent-free coupling of **10a** with **11a** in an equimolar ratio under elevated temperature offers an efficient eco-friendly approach to synthesize functionalized schizocommunin analogues. It is important to note that, reaction is highly diastereoselective having exclusive formation of the (*E*)-isomer and this stereochemistry was well confirmed by single-crystal X-ray diffraction analysis of **12a** and **12c** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Representative images of the single-crystal X-ray diffraction structures of **12a** (CCDC-1902044) and **12c** (CCDC-1893810) showing the diastereoselective exclusive formation of (*E*)-isomer.](ao-2019-01514v_0002){#fig2}

###### Optimization of Reaction Conditions[a](#t1fn1){ref-type="table-fn"}

![](ao-2019-01514v_0005){#GRAPHIC-d7e479-autogenerated}

  entry                                catalyst (30 mol %)   solvent           temp. (°C)   time (h)   yield **12a** (%)[a](#t1fn1){ref-type="table-fn"}
  ------------------------------------ --------------------- ----------------- ------------ ---------- ---------------------------------------------------
  1                                    AcOH                  EtOH              80           4          26
  2                                    HCl                   EtOH              80           4          14
  3                                    H~2~SO~4~             EtOH              80           4          \<10
  4                                    PTSA                  EtOH              80           4          18
  5                                    CSA                   EtOH              80           4          \<10
  6                                    BF~3~-OEt~2~          EtOH              80           4          17
  7                                    TFA                   EtOH              80           4          20
  8                                    TFA                   ethylene glycol   80           4          13
  9                                    boric acid            EtOH              80           4          25
  10                                   boric acid            ethylene glycol   80           4          17
  11                                   boric acid            water             80           4          34
  12                                                         water             100          4          13
  13                                                                           100          24         24
  14                                                                           140          10         53
  15                                                                           160          10         83
  16                                                                           180          6          93
  17                                                                           180          8          92
  18                                                                           180          5          88
  19[b](#t1fn2){ref-type="table-fn"}                                           25           1           

Yields are isolated.

Under grinding condition.

Next, we started exploring the scope of the reaction using various substituted quinazolinones and isatins under the optimized reaction conditions ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Isatins bearing electron-withdrawing functional groups such as CN, Cl, Br, COCH~3~, and CF~3~ afforded corresponding products **12a--12ae** in almost quantitative yields (up to 97%). It is notable that the iodo-functionality also survived in the optimized reaction conditions (**12ab**) and provides further possibilities of the diversification, which otherwise would be challenging by the transition-metal-catalyzed methodologies. The overall yields were excellent in all the cases and no column chromatography was required for the purification of the schizocommunin derivatives (**12a--12ae**).

###### Scope of the Reaction[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2019-01514v_0006){#gr5}

Yields are isolated.

*E* selectivity was \>99% in all the synthesized compounds calculated by ^1^H NMR of crude reaction mixture after completion.

Yield (4.39 g of **12a**) when reaction was carried out at 10 mmol scale.

Additionally, various green chemistry parameters were investigated and demonstrated by the green assessment diagram for the synthesis of schizocommunin derivatives ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Our developed methodology has remarkable advantages in terms of several green parameters, for example, atom economy of the synthesis of **12a** was reached 96.51%; carbon efficiency of the reaction was 100%; reaction mass efficiency was observed up to 89.74%; and most importantly the *E*-factor was reduced to 0.11 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Besides aforementioned improvements in the synthesis of schizocommunin derivatives, no need of the purification by column chromatography was the additional advantage associated with the developed method.

![Green matrix: a quick assessment of the improvement of schizocommunin derivative synthesis.](ao-2019-01514v_0003){#fig3}

Because of the potential cytotoxicity profile of the natural product schizocommunin against murine lymphoma cells,^[@ref8],[@ref9]^ it was anticipated that the analogues of schizocommunin would display promising cytotoxic activity. Thus, the selected synthesized Schizocommunin analogues were evaluated for their cytotoxic activity against three human cancer cell lines, that is, A549 (lung cancer), MCF-7 (breast cancer), and PC-3 (prostate cancer) using an azolium-based colorimetric cytotoxicity assay (MTT assay).^[@ref12]^ Compounds **12i**, **12p**, **12ac**, and **12ae** exhibited above 50% cytotoxicity at 10 μM concentration. These compounds were further selected to evaluate concentration-dependent responses and displayed promising antiproliferative activity with IC~50~ values ranging from 3.21 ± 0.21 to 14.56 ± 0.17 μM ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). The compound **12ac** displayed significant antiproliferative activity against all the screened cancer cell lines. This exciting preliminary antiproliferative activity profile of this series of schizocommunin analogues further opens a new way to get a novel drug lead in cancer treatment.

###### IC~50~ Values[a](#t3fn1){ref-type="table-fn"} (in μM) of Some Selected Schizocommunin Analogues in Human Cancer Cell Lines

  no.   compounds         A549 (lung cancer)   MCF-7 (breast cancer)   PC-3 (prostate cancer)
  ----- ----------------- -------------------- ----------------------- ------------------------
  1     **12a**           \>15                 \>15                    \>15
  2     **12i**           \>15                 **12.45 ± 0.33**        **14.56 ± 0.17**
  3     **12p**           \>15                 \>15                    **5.43 ± 0.64**
  4     **12x**           \>15                 \>15                    \>15
  5     **12ab**          \>15                 \>15                    \>15
  6     **12ac**          **8.52 ± 0.52**      **4.73 ± 0.74**         **3.21 ± 0.21**
  7     **12ae**          **11.24 ± 0.10**     **13.47 ± 0.18**        \>15
  8     **doxorubicin**   1.64 ± 0.35          0.14 ± 0.10             0.55 ± 0.32

50% inhibitory concentration after 48 h of drug treatment.

In order to understand the mechanism of anticancer activity of the inhibitor (**12ac**), molecular docking study was performed on the protein structure of cyclin-dependent kinase 2 (CDK2) enzyme ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).^[@cit13a],[@cit13b]^ Prior docking, the molecular structure of the ligand **12ac** was energy minimized with the aid of the MMFF94x force field to attain the low-energy conformation. The free energy binding score of the compound **12ac** was −6.99 kcal/mol and was very close to the binding energy value (−8.19 kcal/mol) of the reference drug sunitinib. An analysis of protein--ligand interactions showed that the −C=O group and nitrogen atoms in the quinazolin-4(3*H*)-one and oxoindolin-3-ylidene moieties are strongly interacted electrostatically with the acidic and basic amino acid domains of Glu8, Asp86, Lys88, Gln131, Lys9, Lys20, Lys89, and Gly11. The 3-chlorobenzyl group at the quinazolin-4(3*H*)-one ring interacted by means of hydrophobic domains of Leu134, Leu298, Val18, Phe82, Ala31, and Leu83. The benzyl moiety and 5-chlorophenyl at 2-oxoindolin-3-ylidene moieties are completely exposed to the solvent area of the protein. This indicated that, such types of projective groups are not important for the inhibition of the CDK2 enzyme. This study strongly demonstrated the key features responsible for the inhibitory activity as well as design of analogues against the CDK2 target.

![3D and 2D overlay illustration of inhibitor **12ac** in the complex with cyclin-dependent kinase 2 (CDK2) enzyme (PDB code---[3TI1]{.smallcaps}).](ao-2019-01514v_0004){#fig4}

Conclusions {#sec3}
===========

In summary, we have described an environmentally benign, straightforward access for the synthesis of diastereoselective schizocommunin derivatives in the absence of catalyst and solvent in excellent yields. The advantages of the developed methodology are experimental simplicity, easy work-up, and excellent yields of products. Additionally, the product isolation does not require purification by column chromatography. This eco-friendly methodology also eliminates toxic metal catalyst-related environmental hazards and pollutions along with increase in atomic economy. Furthermore, the preliminary cytotoxic activity of selected compounds revealed that the promising cytotoxic profile in A549, MCF-7, and PC-3 human cancer cell lines. The in silico molecular docking simulation studies of compound **12ac** effectively validated the in vitro experimental results and worthy of further structural optimization for the development in the anticancer drug discovery process.

Experimental Section {#sec4}
====================

General {#sec4.1}
-------

All reactions were carried out in oven- or flame-dried glassware unless otherwise noted. Except as otherwise indicated, all reactions were magnetically stirred and monitored by analytical thin-layer chromatography (TLC) using precoated silica gel glass plates (0.25 mm) with the F254 indicator. Visualization was accomplished by UV light (254 nm). Column chromatography was performed using a silica gel 100--200 mesh. Yields refer to pure compounds, unless otherwise noted. Commercial grade reagents and solvents were used without further purification. ^1^H and ^13^C NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer using CDCl~3~/DMSO-*d*~6~ as a solvent for deuterium locking with temperature 298 K. Chemical shifts are given in ppm with TMS as an internal reference. J values are given in Hertz. High-resolution mass spectra were determined with a quadrupole time-of-flight mass spectrometer.

General Procedure for the Synthesis of Schizocommunin Derivatives (**12a**) {#sec4.2}
---------------------------------------------------------------------------

3-(4-Methoxybenzyl)-2-methylquinazolin-4(3*H*)-one (**10a**, 1 mmol, 280 mg) and 1-benzylindoline-2,3-dione (**11a**, 1 mmol, 237 mg) were added in a vial. The reaction mixture was heated at 180 °C. The progress of the reaction was monitored by TLC and after 6 h, the starting materials disappeared. The solidified reaction mixture was cooled down to room temperature and added ethanol (5 mL), stirred for 30 min, filtered off, which afforded the pure product **12a** as a reddish orange solid (93% yield, 464 mg).

### (*E*)-2-((1-Benzyl-2-oxoindolin-3-ylidene)methyl)-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one (**12a**) {#sec4.2.1}

It was obtained as a reddish orange solid, yield 93%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.71 (s, 3H), 4.97 (s, 2H), 5.41 (s, 2H), 6.69 (d, *J* = 8 Hz, 1H), 6.78 (d, *J* = 8.8 Hz, 2H), 6.87 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 0.8 Hz, 1H), 7.19 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.28--7.36 (m, 7H), 7.57 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.63 (s, 1H), 7.76 (d, *J* = 7.2 Hz, 1H), 7.81 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.93 (d, *J* = 7.6 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.1, 55.2, 109.3, 114.3, 120.0, 121.4, 122.5, 125.6, 126.7, 127.3, 127.4, 127.6, 127.8, 127.9, 127.9, 128.8, 128.9, 131.7, 133.6, 134.7, 135.5, 144.7, 146.9, 150.7, 159.2, 161.9, 167.6. HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~25~N~3~O~3~Na, 522.1788; found, 522.1782.

### (*E*)-2-((1-Allyl-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12b**) {#sec4.2.2}

It was obtained as a reddish orange solid, yield 87%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.38 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.6 Hz, 2H), 5.23 (d, *J* = 1.2 Hz, 1H), 5.25 (dd, *J*~1~ = 4 Hz, *J*~2~ = 0.8 Hz, 1H), 5.45 (s, 2H), 5.79--5.89 (m, 1H), 6.80 (d, *J* = 7.6 Hz, 1H), 6.92 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.2 Hz, 2H), 6.99 (dt, *J*~1~ = 9.6 Hz, *J*~2~ = 2 Hz, 1H), 7.08 (dd, *J*~1~ = 7.6 Hz, *J*~2~ = 0.4 Hz, 1H), 7.24--7.32 (m, 2H), 7.49 (s, 1H), 7.60 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.78 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.84 (td, *J*~1~ = 7.2 Hz, *J*~2~ = 1.6 Hz, 1H), 7.99 (d, *J* = 7.6 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.4, 47.1, 109.3, 114.1, 114.4, 114.9, 115.1, 117.8, 119.8, 121.2, 122.4, 122.8, 122.8, 124.7, 126.8, 127.4, 127.7, 128.1, 130.5, 130.6, 131.0, 131.9, 134.1, 134.9, 138.1, 138.1, 144.9, 146.9, 150.4, 161.8, 164.3, 167.1; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~20~FN~3~O~2~Na, 460.1432; found, 460.1424.

### (*E*)-2-((1-Allyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12c**) {#sec4.2.3}

It was obtained as a reddish orange solid, yield 85%. *R*~f~ = 0.62 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.35 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.2 Hz, 2H), 5.19--5.26 (m, 2H), 5.49 (s, 2H), 5.76--6.86 (m, 1H), 6.68 (d, *J* = 8.4 Hz, 1H), 6.93 (td, *J*~1~ = 8.2 Hz, *J*~2~ = 2 Hz, 1H), 7.02 (d, *J* = 9.6 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.28--7.33 (m, 1H), 7.42 (dd, *J*~1~ = 8.4 Hz, *J*~2~ = 2 Hz, 1H), 7.55 (s, 1H), 7.61 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.83 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.87 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H), 8.66 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.5, 46.9, 110.5, 114.1, 114.4, 115.0, 115.2, 118.0, 121.2, 121.7, 122.8, 122.8, 126.2, 127.5, 127.5, 128.4, 130.6, 130.7, 130.7, 131.1, 133.1, 134.3, 135.1, 138.1, 138.2, 143.9, 146.6, 149.7, 161.8, 161.9, 164.3, 166.8; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~19~BrFN~3~O~2~Na, 538.0537; found, 538.0534.

### (*E*)-3-Benzyl-2-((2-oxo-1-(prop-2-yn-1-yl)indolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12d**) {#sec4.2.4}

It was obtained as a reddish orange solid, yield 84%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.25 (t, *J* = 2.4 Hz, 1H), 4.55 (d, *J* = 2.8 Hz, 2H), 5.46 (s, 2H), 6.96 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 0.8 Hz, 1H), 7.02 (d, *J* = 7.6 Hz, 1H), 7.25--7.31 (m, 5H), 7.35 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.54 (s, 1H), 7.59 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.77 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.4 Hz, 1H), 7.83 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.99 (d, *J* = 7.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 29.3, 47.6, 72.4, 76.5, 109.3, 119.9, 121.4, 122.8, 125.7, 126.9, 127.3, 127.4, 127.6, 128.0, 128.1, 128.9, 131.9, 133.5, 134.8, 135.6, 143.7, 146.9, 150.6, 161.9, 166.5; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~19~N~3~O~2~Na, 440.1369; found, 440.1356.

### (*E*)-2-((1-Benzyl-2-oxoindolin-3-ylidene)methyl)-3-(2-methoxybenzyl)quinazolin-4(3*H*)-one (**12e**) {#sec4.2.5}

It was obtained as a reddish orange solid, yield 91%. *R*~f~ = 0.62 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.85 (s, 3H), 4.94 (s, 2H), 5.48 (s, 2H), 6.68 (d, *J* = 8 Hz, 1H), 6.80 (t, *J* = 7.2 Hz, 1H), 6.84 (d, *J* = 8 Hz, 1H), 6.87 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.08 (d, *J* = 7.6 Hz, 1H), 7.18--7.22 (m, 2H), 7.27--7.34 (m, 5H), 7.57 (s, 1H), 7.59 (dd, *J*~1~ = 7.6 Hz, *J*~2~ = 0.8 Hz, 1H), 7.76 (d, *J* = 8 Hz, 1H), 7.81 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.92 (d, *J* = 7.2 Hz, 1H), 8.40 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.9, 43.8, 55.4, 109.2, 110.4, 120.1, 120.7, 121.4, 122.4, 123.6, 126.1, 126.5, 127.3, 127.3, 127.5, 127.7, 127.8, 128.0, 128.8, 129.0, 131.6, 133.4, 134.6, 135.6, 144.6, 146.9, 151.1, 156.7, 162.0, 167.5; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~25~N~3~O~3~Na, 522.1788; found, 522.1786.

### (*E*)-2-((5-Bromo-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinolin-4(3*H*)-one (**12f**) {#sec4.2.6}

It was obtained as a reddish orange solid, yield 95%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:4). ^1^H NMR (400 MHz, DMSO): δ 4.61 (S, 2H), 5.95 (d, *J* = 8.4 Hz, 1H), 6.21 (d, *J* = 7.6 Hz, 2H), 6.27 (d, *J* = 9.6 Hz, 1H), 6.43--4.51 (m, 2H), 6.60 (dd, *J*~1~ = 8.4 Hz, *J*~2~ = 1.6 Hz, 1H), 6.81 (t, *J* = 7.6 Hz, 1H), 6.88 (d, *J* = 8 Hz, 1H), 7.11 (t, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.6 Hz, 1H), 7.57 (s, 1H), 10.01 (s, 1H); ^13^C NMR (100 MHz, DMSO): δ 46.3, 112.0, 113.0, 113.5, 113.7, 114.3, 114.5, 120.9, 122.0, 122.5, 126.1, 126.9, 128.3, 130.0, 130.8, 130.9, 133.2, 134.2, 135.2, 139.2, 139.3, 143.5, 146.4, 150.3, 161.1, 163.5, 167.6; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~24~H~15~BrFN~3~O~2~Na, 498.0224; found, 498.0211.

### (*E*)-2-((1-Allyl-2-oxoindolin-3-ylidene)methyl)-3-(4-methylbenzyl)quinazolin-4(3*H*)-one (**12g**) {#sec4.2.7}

It was obtained as a reddish orange solid, yield 86%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.26 (s, 3H), 4.38 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.6 Hz, 2H), 5.22 (t, *J* = 1.2 Hz, 1H), 5.25 (dd, *J*~1~ = 6.4 Hz, *J*~2~ = 0.8 Hz, 1H), 5.42 (s, 2H), 5.80--5.89 (m, 1H), 6.79 (d, *J* = 8 Hz, 1H), 6.90 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.2 Hz, 1H), 7.07 (d, *J* = 8 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.27 (td, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.56 (s, 1H), 7.57 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.76 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.81 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 1H), 7.98 (d, *J* = 7.2 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 21.1, 42.4, 47.4, 109.2, 117.7, 120.0, 121.4, 122.4, 125.4, 126.8, 127.4, 127.4, 127.6, 127.9, 128.9, 129.1, 129.6, 131.1, 131.7, 132.7, 133.7, 134.7, 137.7, 144.8, 146.9, 150.8, 161.9, 167.2; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~23~N~3~O~2~Na, 456.1682; found, 456.1676.

### (*E*)-2-((1-Allyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(4-methylbenzyl)quinazolin-4(3*H*)-one (**12h**) {#sec4.2.8}

It was obtained as a reddish orange solid, yield 86%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.27 (s, 3H), 4.35 (d, *J* = 5.2 Hz, 2H), 5.19--5.25 (m, 2H), 5.45 (s, 2H), 5.76--5.86 (m, 1H), 6.66 (d, *J* = 8.4 Hz, 1H), 7.10 (d, *J* = 8 Hz, 2H), 7.22 (d, *J* = 8 Hz, 2H), 7.39 (dd, *J*~1~ = 8.4 Hz, *J*~2~ = 2 Hz, 1H), 7.58--7.63 (m, 2H), 7.81 (d, *J* = 7.6 Hz, 1H), 7.84 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 8.62 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 21.1, 42.5, 47.2, 110.4, 114.9, 117.9, 121.4, 121.8, 126.9, 127.3, 127.4, 127.5, 128.2, 129.7, 130.8, 131.0, 132.7, 132.8, 134.1, 134.9, 137.8, 143.8, 146.7, 150.1, 161.9, 166.9; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~22~BrN~3~O~2~Na, 534.0788; found, 534.0763.

### (*E*)-3-Benzyl-2-((5-bromo-2-oxo-1-(prop-2-yn-1-yl)indolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12i**) {#sec4.2.9}

It was obtained as a reddish orange solid, yield 88%. *R*~f~ = 0.58 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.26 (t, *J* = 2.4 Hz, 1H), 4.53 (d, *J* = 2.4 Hz, 2H), 5.50 (s, 2H), 6.91 (d, *J* = 8 Hz, 1H), 7.24--7.27 (m, 1H), 7.32--7.34 (m, 4H), 7.49 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 2 Hz, 1H), 7.61 (s, 1H), 7.63 (dd, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.82 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.4 Hz, 1H), 7.87 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 1.2 Hz, 1H), 8.64 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 29.4, 47.4, 72.8, 76.1, 110.6, 115.4, 121.4, 121.8, 127.1, 127.2, 127.5, 128.1, 129.0, 131.0, 132.5, 134.3, 135.0, 135.6, 142.6, 146.6, 149.8, 161.9, 166.3; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~18~BrN~3~O~2~Na, 518.0475; found, 518.0458.

### (*E*)-2-((1-Benzyl-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12j**) {#sec4.2.10}

It was obtained as a reddish orange solid, yield 96%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.95 (s, 2H), 5.47 (s, 2H), 6.69 (d, *J* = 8 Hz, 1H), 6.88--6.94 (m, 2H), 7.00 (d, *J* = 9.2 Hz, 1H), 7.09 (d, *J* = 7.6 Hz, 1H), 7.20 (dt, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 2H), 7.27--7.35 (m, 5H), 7.54 (s, 1H), 7.59 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.78 (d, *J* = 7.2 Hz, 1H), 7.84 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.6 Hz, 1H), 7.97 (d, *J* = 7.2 Hz, 1H), 8.41 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.1, 109.4, 114.2, 114.4, 114.9, 115.1, 119.9, 121.2, 122.5, 122.8, 122.8, 124.9, 126.8, 127.3, 127.4, 127.9, 127.8, 128.1, 128.8, 130.5, 130.6, 131.9, 134.0, 134.9, 135.4, 138.1, 138.2, 144.8, 146.9, 150.5, 161.8, 164.3, 167.5; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~31~H~22~FN~3~O~2~Na, 510.1588; found, 510.1562.

### (*E*)-3-(2-Methoxybenzyl)-2-((2-oxoindolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12k**) {#sec4.2.11}

It was obtained as a reddish orange solid, yield 96%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:4). ^1^H NMR (400 MHz, DMSO): δ 3.82 (s, 3H), 5.36 (s, 2H), 6.80 (d, *J* = 8 Hz, 2H), 6.91 (dd, *J*~1~ = 7.4 Hz, *J*~2~ = 1.6 Hz, 1H), 7.00 (d, *J* = 7.6 Hz, 1H), 7.20--7.22 (m, 1H), 7.25 (s, 1H), 7.45 (dd, *J*~1~ = 8 Hz, *J*~2~ = 2 Hz, 1H), 7.66 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.73 (d, *J* = 8 Hz, 1H), 7.96 (td, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 8.25 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 1.2 Hz, 1H), 8.46 (d, *J* = 2 Hz, 1H), 10.87 (s, 1H); ^13^C NMR (100 MHz, DMSO): δ 42.3, 55.5, 110.9, 111.9, 112.9, 120.5, 120.8, 122.1, 123.7, 126.4, 126.8, 126.8, 128.2, 128.8, 130.1, 133.1, 134.2, 135.1, 143.5, 146.3, 150.5, 156.3, 161.1, 167.7; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~25~H~18~BrN~3~O~3~Na, 510.0424; found, 510.0443.

### (*E*)-2-((1-Allyl-2-oxoindolin-3-ylidene)methyl)-3-(2-methoxybenzyl)quinazolin-4(3*H*)-one (**12l**) {#sec4.2.12}

It was obtained as a reddish orange solid, yield 85%. *R*~f~ = 0.63 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.85 (s, 3H), 4.36 (d, *J* = 5.2 Hz, 2H), 5.21 (s, 1H), 5.24 (d, *J* = 5.2 Hz, 1H), 5.45 (s, 2H), 5.78--5.88 (m, 1H), 6.78--6.86 (m, 3H), 6.90 (t, *J* = 7.6 Hz, 1H), 7.07 (d, *J* = 7.2 Hz, 1H), 7.18 (t, *J* = 7.6 Hz, 1H), 7.28 (d, *J* = 7.6 Hz, 1H), 7.52 (s, 1H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.76 (d, *J* = 8 Hz, 1H), 7.82 (t, *J* = 6.8 Hz, 1H), 7.92 (d, *J* = 7.6 Hz, 1H), 8.40 (d, *J* = 7.6 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.3, 42.9, 55.4, 109.1, 110.4, 117.6, 120.0, 120.7, 121.4, 122.3, 123.5, 125.9, 126.5, 127.3, 127.5, 127.8, 127.9, 129.0, 131.2, 131.6, 133.5, 134.6, 144.7, 146.9, 151.1, 156.7, 162.0, 167.1; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~23~N~3~O~3~Na, 472.1624; found, 472.1613.

### (*E*)-2-((1-Allyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(2-methoxybenzyl)quinazolin-4(3*H*)-one (**12m**) {#sec4.2.13}

It was obtained as a reddish orange solid, yield 88%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.87 (s, 3H), 4.33 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.6 Hz, 2H), 5.18--5.24 (m, 2H), 5.50 (s, 2H), 5.75--5.85 (m, 1H), 6.65 (d, *J* = 8.4 Hz, 1H), 6.81 (t, *J* = 7.6 Hz, 1H), 6.85 (d, *J* = 8 Hz, 1H), 7.07 (dd, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.18 (td, *J*~1~ = 8.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.39 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 2 Hz, 1H), 7.58 (s, 1H), 7.60 (dd, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.81 (d, *J* = 7.2 Hz, 1H), 7.84 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.2 Hz, 1H), 8.40 (dd, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H), 8.56 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.4, 42.6, 55.5, 110.3, 110.4, 114.9, 117.8, 120.7, 121.4, 121.9, 123.7, 127.4, 127.5, 128.0, 128.1, 129.1, 130.7, 130.8, 132.6, 133.9, 134.8, 143.7, 146.7, 150.4, 156.7, 162.0, 166.8; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~22~BrN~3~O~3~Na, 550.0737; found, 550.0735.

### (*E*)-2-((5-Bromo-2-oxo-1-(prop-2-yn-1-yl)indolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12n**) {#sec4.2.14}

It was obtained as a reddish orange solid, yield 82%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.26 (t, *J* = 2.4 Hz, 1H), 4.53 (d, *J* = 2.4 Hz, 2H), 5.48 (s, 2H), 6.92 (d, *J* = 8.4 Hz, 1H), 6.96 (dd, *J*~1~ = 8.4 Hz, *J*~2~ = 2 Hz, 1H), 7.02 (d, *J* = 9.6 Hz, 1H), 7.11 (d, *J* = 8 Hz, 1H), 7.29--7.34 (m, 1H), 7.50 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 2 Hz, 1H), 7.55 (s, 1H), 7.62 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.83 (d, *J* = 7.2 Hz, 1H), 7.88 (td, *J*~1~ = 6.8 Hz, *J*~2~ = 1.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 8.68 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 29.4, 46.9, 72.8, 76.1, 110.7, 114.1, 114.3, 115.1, 115.3, 115.5, 121.2, 121.7, 122.7, 122.8, 126.6, 127.5, 127.6, 128.5, 130.6, 130.7, 131.2, 132.8, 134.5, 135.2, 138.0, 138.1, 142.7, 146.6, 149.6, 161.8, 161.9, 164.3, 166.2; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~17~BrFN~3~O~2~Na, 536.0380; found, 536.0339.

### (*E*)-2-((1-Benzyl-2-oxoindolin-3-ylidene)methyl)-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one (**12o**) {#sec4.2.15}

It was obtained as a reddish orange solid, yield 95%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.95 (s, 2H), 5.52 (s, 2H), 6.68 (d, *J* = 7.6 Hz, 1H), 6.86 (t, *J* = 7.6 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.27--7.37 (m, 5H), 7.39 (d, *J* = 7.6 Hz, 1H), 7.46--7.52 (m, 2H), 7.53 (s, 1H), 7.56 (s, 1H), 7.60 (t, *J* = 6.8 Hz, 1H), 7.79 (d, *J* = 8 Hz, 1H), 7.85 (t, *J* = 8 Hz, 2H), 8.42 (d, *J* = 8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.1, 109.4, 119.8, 121.2, 122.5, 124.2, 124.2, 124.6, 124.9, 124.9, 126.6, 127.3, 127.5, 127.7, 127.8, 128.2, 128.8, 129.5, 130.7, 132.0, 134.2, 135.0, 135.4, 136.8, 144.8, 146.9, 150.3, 161.8, 167.4; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~22~F~3~N~3~O~2~Na, 560.1556; found, 560.1523.

### (*E*)-3-(2-Methoxybenzyl)-2-((2-oxoindolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12p**) {#sec4.2.16}

It was obtained as a reddish orange solid, yield 91%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:4). ^1^H NMR (400 MHz, CDCl~3~): δ 3.86 (s, 3H), 5.46 (s, 2H), 6.80--6.87 (m, 3H), 6.90 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 0.8 Hz, 1H), 7.08 (dd, *J*~1~ = 7.6 Hz, *J*~2~ = 1.2 Hz, 1H), 7.18 (td, *J*~1~ = 8 Hz, *J*~2~ = 1.6 Hz, 1H), 7.25 (td, *J*~1~ = 8.6 Hz, *J*~2~ = 1.2 Hz, 1H), 7.47 (s, 1H), 7.57 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.69 (s, 1H), 7.77 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.82 (td, *J*~1~ = 7.2 Hz, *J*~2~ = 1.6 Hz, 1H), 7.92 (d, *J* = 7.2 Hz, 1H), 8.40 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.8, 55.4, 109.9, 110.4, 120.6, 120.7, 121.4, 122.4, 123.5, 126.0, 126.9, 127.3, 127.5, 127.9, 128.0, 129.0, 131.7, 133.7, 134.7, 142.5, 146.9, 150.9, 156.7, 162.0, 168.5; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~25~H~19~N~3~O~3~Na, 432.1319; found, 432.1313.

### (*E*)-2-((1-Allyl-2-oxoindolin-3-ylidene)methyl)-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one (**12q**) {#sec4.2.17}

It was obtained as a reddish orange solid, yield 82%. *R*~f~ = 0.55 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.73 (s, 3H), 4.39 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.6 Hz, 2H), 5.24 (s, 1H), 5.26 (dd, *J*~1~ = 8.6 Hz, *J*~2~ = 1.2 Hz, 1H), 5.40 (s, 2H), 5.81--5.91 (m, 1H), 6.80 (dd, *J*~1~ = 6.8 Hz, *J*~2~ = 2 Hz, 3H), 6.91 (td, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.28 (d, *J* = 8.4, 3H), 7.37 (d, *J* = 4.2, 1H), 7.58 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 2H), 7.77 (d, *J* = 7.6 Hz, 1H), 7.82 (td, *J*~1~ = 5.6 Hz, *J*~2~ = 1.6 Hz, 1H), 7.97 (d, *J* = 7.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.5, 47.1, 55.2, 109.2, 114.3, 117.8, 120.0, 121.4, 122.4, 125.4, 126.8, 126.9, 127.4, 127.6, 127.9, 127.9, 127.9, 128.6, 128.9, 131.1, 131.7, 133.6, 134.7, 144.8, 146.9, 150.7, 159.3, 161.9, 167.2; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~23~N~3~O~3~Na, 472.1632; found, 472.1629.

### (*E*)-2-((1-Allyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one (**12r**) {#sec4.2.18}

It was obtained as a reddish orange solid, yield 84%. *R*~f~ = 0.58 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.74 (s, 3H), 4.36 (dt, *J*~1~ = 5.2 Hz, *J*~2~ = 1.6 Hz, 2H), 5.20--5.26 (m, 2H), 5.44 (s, 2H), 5.78--5.87 (m, 1H), 6.68 (d, *J* = 8.4 Hz, 1H), 6.82 (d, *J* = 8.8 Hz, 2H), 7.29 (d, *J* = 8.8 Hz, 2H), 7.41 (dd, *J*~1~ = 8.6 Hz, *J*~2~ = 2 Hz, 1H), 7.59 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.67 (s, 1H), 7.81 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.85 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 1.2 Hz, 1H), 8.60 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.5, 46.9, 55.2, 110.5, 113.4, 114.4, 115.0, 117.9, 121.5, 121.8, 126.9, 127.5, 127.9, 128.3, 128.9, 130.8, 130.9, 132.7, 134.2, 134.9, 143.8, 146.7, 150.1, 159.3, 161.9, 166.9; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~28~H~22~BrN~3~O~3~Na, 550.0737; found, 550.0734.

### (*E*)-2-((1-Allyl-5-chloro-2-oxoindolin-3-ylidene)methyl)-3-benzylquinazolin-4(3*H*)-one (**12s**) {#sec4.2.19}

It was obtained as a reddish orange solid, yield 91%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (500 MHz, CDCl~3~): δ 4.37 (d, *J* = 4.5 Hz, 2H), 5.24 (d, *J* = 7.6 Hz, 2H), 5.46 (s, 2H), 5.78--5.86 (m, 1H), 6.73 (d, *J* = 8.5 Hz, 1H), 7.23--7.29 (m, 6H), 7.55 (s, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.83 (d, *J* = 8 Hz, 1H), 7.88 (t, *J* = 7.5 Hz, 1H), 8.38 (s, 1H), 8.42 (d, *J* = 8 Hz, 1H); ^13^C NMR (125 MHz, CDCl~3~): δ 42.6, 46.9, 110.1, 117.9, 121.2, 125.4, 126.1, 127.3, 127.5, 127.6, 127.8, 127.9, 128.3, 128.4, 130.3, 130.7, 131.5, 133.2, 134.9, 135.2, 137.7, 143.4, 146.6, 149.8, 161.8, 166.9; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~20~ClN~3~O~2~Na, 476.1136; found, 476.1123.

### (*E*)-2-((1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one (**12t**) {#sec4.2.20}

It was obtained as a reddish orange solid, yield 95%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.73 (s, 3H), 4.94 (s, 2H), 5.45 (s, 2H), 6.56 (d, *J* = 8 Hz, 1H), 6.82 (d, *J* = 7.6 Hz, 2H), 7.26--7.32 (m, 8H), 7.59 (t, *J* = 6 Hz, 1H), 7.71 (s, 1H), 7.80--7.86 (m, 2H), 8.42 (d, *J* = 7.2 Hz, 1H), 8.56 (s, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 46.9, 55.2, 110.5, 114.4, 115.1, 121.5, 121.9, 127.1, 127.2, 127.5, 127.5, 127.9, 128.3, 128.9, 128.9, 130.9, 132.6, 134.2, 134.9, 135.1, 143.7, 146.7, 150.1, 159.3, 161.9, 167.3; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~24~BrN~3~O~3~Na, 600.0893; found, 600.0847.

### (*E*)-2-((1-Allyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-benzylquinazolin-4(3*H*)-one (**12u**) {#sec4.2.21}

It was obtained as a reddish orange solid, yield 82%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.36 (d, *J* = 5.2 Hz, 2H), 5.19 (td, *J*~1~ = 8.8 Hz, *J*~2~ = 0.8 Hz, 2H), 5.51 (s, 2H), 5.76--5.86 (m, 1H), 6.68 (d, *J* = 8.4 Hz, 1H), 7.22--7.26 (m, 1H), 7.30--7.36 (m, 4H), 7.42 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 2 Hz, 1H), 7.61--7.65 (m, 2H), 7.82 (d, *J* = 8 Hz, 1H), 7.87 (td, *J*~1~ = 6.6 Hz, *J*~2~ = 1.2 Hz, 1H), 8.43 (dd, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 8.62 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.5, 47.4, 110.5, 115.0, 117.9, 121.4, 121.8, 126.7, 127.3, 127.5, 127.5, 128.0, 128.3, 129.0, 130.7, 130.9, 132.8, 134.2, 135.0, 135.7, 143.8, 146.7, 150.0, 161.9, 166.9; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~27~H~20~BrN~3~O~2~Na, 520.0631; found, 520.0627.

### (*E*)-2-((1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12v**) {#sec4.2.22}

It was obtained as a reddish orange solid, yield 96%. *R*~f~ = 0.65 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.92 (d, *J* = 4.4 Hz, 2H), 5.49 (d, *J* = 3.6 Hz, 2H), 6.55--6.58 (m, 1H), 6.93--6.96 (m, 1H), 7.03 (d, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 6.4 Hz, 1H), 7.26--7.35 (m, 7H), 7.59--7.64 (m, 2H), 7.83--7.90 (m, 2H), 8.41 (d, *J* = 7.6 Hz, 1H), 8.62 (d, *J* = 3.6 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 46.9, 110.6, 114.2, 114.4, 115.0, 115.1, 115.2, 121.3, 121.8, 122.8, 126.4, 127.2, 127.5, 127.9, 128.5, 128.9, 130.6, 130.7, 131.0, 133.1, 134.4, 134.9, 135.2, 138.2, 138.2, 143.8, 146.6, 149.8, 161.8, 161.9, 164.4, 167.2; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~31~H~21~BrFN~3~O~2~Na, 588.0693; found, 588.0678.

### (*E*)-2-((1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(2-methoxybenzyl)quinazolin-4(3*H*)-one (**12w**) {#sec4.2.23}

It was obtained as a reddish orange solid, yield 95%. *R*~f~ = 0.60 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.87 (s, 3H), 4.91 (s, 2H), 5.52 (s, 2H), 6.54 (d, *J* = 8.4 Hz, 1H), 6.81--6.87 (m, 2H), 7.09 (d, *J* = 7.6 Hz, 1H), 7.18 (td, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 7.24--7.33 (m, 6H), 7.58 (t, *J* = 6.8 Hz, 1H), 7.63 (s, 1H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.84 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 8.41 (d, *J* = 8 Hz, 1H), 8.54 (d, *J* = 1.6 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.5, 43.8, 55.5, 110.4, 114.9, 120.7, 121.4, 121.0, 123.7, 127.2, 127.4, 127.4, 127.7, 127.9, 128.1, 128.1, 128.9, 129.1, 130.7, 132.5, 133.9, 134.8, 135.1, 143.6, 146.7, 150.4, 156.7, 161.9, 167.2; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~24~BrN~3~O~3~Na, 600.0893; found, 600.0884.

### (*E*)-3-Benzyl-2-((1-benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12x**) {#sec4.2.24}

It was obtained as a reddish orange solid, yield 97%. *R*~f~ = 0.70 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.93 (s, 2H), 5.52 (s, 2H), 6.56 (d, *J* = 8.4 Hz, 1H), 7.23--7.36 (m, 11H), 7.61 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 7.66 (s, 1H), 7.82 (d, *J* = 7.6 Hz, 1H), 7.86 (td, *J*~1~ = 6.8 Hz, *J*~2~ = 1.6 Hz, 1H), 8.43 (dd, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 8.59 (d, *J* = 1.6 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.4, 110.6, 115.1, 121.4, 121.8, 126.8, 127.2, 127.3, 127.5, 127.5, 127.9, 128.0, 128.3, 128.9, 129.0, 130.9, 132.8, 134,2, 134.9, 135.0, 135.7, 143.7, 146.6, 150.0, 161.9, 167.3; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~31~H~22~BrN~3~O~2~Na, 570.0788; found, 570.0787.

### (*E*)-2-((1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one (**12y**) {#sec4.2.25}

It was obtained as a reddish orange solid, yield 92%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.92 (s, 2H), 5.56 (s, 2H), 6.55 (d, *J* = 8 Hz, 1H), 7.26--7.34 (m, 6H), 7.43--7.65 (m, 6H), 7.82--7.89 (m, 2H), 8.42 (d, *J* = 7.6 Hz, 1H), 8.56 (s, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 46.9, 110.7, 115.1, 121.2, 121.7, 124.2, 124.3, 125.0, 125.0, 126.1, 127.2, 127.6, 127.9, 128.5, 128.9, 129.6, 130.7, 130.9, 131.2, 133.2, 134.4, 134.9, 135.2, 136.8, 143.8, 146.6, 149.7, 161.8, 167.1; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~21~BrF~3~N~3~O~2~Na, 638.0661; found, 638.0643.

### (*E*)-2-((1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)methyl)-3-(4-methylbenzyl)quinazolin-4(3*H*)-one (**12z**) {#sec4.2.26}

It was obtained as a reddish orange solid, yield 84%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 2.26 (s, 3H), 4.93 (s, 2H), 5.47 (s, 2H), 6.55 (d, *J* = 8.4 Hz, 1H), 7.09 (d, *J* = 8 Hz, 2H), 7.23--7.33 (m, 8H), 7.59 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.6 Hz, 1H), 7.68 (s, 1H), 7.80 (d, *J* = 7.6, 1H), 7.84 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8.2 Hz, *J*~2~ = 1.2 Hz, 1H), 8.58 (d, *J* = 2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 21.1, 43.9, 47.2, 110.5, 115.1, 121.4, 121.9, 127.0, 127.2, 127.3, 127.5, 127.5, 128.2, 128.9, 129.7, 130.9, 132.7, 132.8, 134.1, 134.9, 135.1, 137.8, 143.7, 146.7, 150.1, 161.9, 167.3; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~24~BrN~3~O~2~Na, 584.0944; found, 584.0929.

### (*E*)-3-Benzyl-2-((1-benzyl-2-oxo-5-phenylindolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12aa**) {#sec4.2.27}

It was obtained as a reddish orange solid, yield 96%. *R*~f~ = 0.66 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.98 (s, 2H), 5.52 (s, 2H), 6.76 (d, *J* = 8 Hz, 1H), 7.27--7.37 (m, 14H), 7.42--7.48 (m, 3H), 7.59 (t, *J* = 6.8 Hz, 1H), 7.65 (s, 1H), 7.81--7.83 (m, 1H), 8.42 (d, *J* = 8 Hz, 1H), 8.56 (d, *J* = 1.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 47.9, 47.5, 109.5, 120.5, 121.4, 125.7, 126.4, 126.5, 126.6, 127.1, 127.3, 127.4, 127.5, 127.8, 127.9, 128.0, 128.1, 128.8, 128.8, 129.0, 130.5, 133.9, 134.7, 135.4, 135.6, 135.7, 140.5, 144.1, 146.8, 150.6, 161.9, 167.7; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~37~H~27~N~3~O~2~Na, 568.1995; found, 568.1987.

### (*E*)-3-Benzyl-2-((1-benzyl-5-iodo-2-oxoindolin-3-ylidene)methyl)quinazolin-4(3*H*)-one (**12ab**) {#sec4.2.28}

It was obtained as a reddish orange solid, yield 85%. *R*~f~ = 0.55 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 4.93 (s, 2H), 5.52 (s, 2H), 6.47 (d, *J* = 8 Hz, 1H), 7.26--7.35 (m, 11H), 7.51--7.53 (m, 1H), 7.65 (s, 1H), 7.84--7.90 (m, 2H), 8.43 (dd, *J*~1~ = 8 Hz, *J*~2~ = 0.8 Hz, 1H), 8.85 (d, *J* = 1.6 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.4, 85.0, 111.2, 121.4, 122.2, 126.7, 127.2, 127.3, 127.5, 127.9, 128.0, 128.3, 128.9, 129.0, 132.6, 134.9, 135.0, 135.7, 136.8, 140.0, 144.3, 146.6, 150.0, 161.9, 167.1; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~31~H~22~IN~3~O~2~Na, 618.0649; found, 618.0635.

### (*E*)-2-((1-Benzyl-5-chloro-2-oxoindolin-3-ylidene)methyl)-3-(3-chlorobenzyl)quinazolin-4(3*H*)-one (**12ac**) {#sec4.2.29}

It was obtained as a reddish orange solid, yield 94%. *R*~f~ = 0.62 (TLC, Hex/EA, 1:1). ^1^H NMR (500 MHz, CDCl~3~): δ 4.95 (s, 2H), 5.49 (s, 2H), 6.61 (d, *J* = 8 Hz, 1H), 7.19--7.33 (m, 10H), 7.60 (s, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.82 (d, *J* = 8 Hz, 1H), 7.88 (t, *J* = 7.5 Hz, 1H), 8.36 (s, 1H), 8.43 (d, *J* = 8 Hz, 1H); ^13^C NMR (125 MHz, CDCl~3~): δ 44.0, 46.9, 110.2, 121.3, 121.3, 125.4, 126.3, 127.2, 127.4, 127.6, 127.6, 127.9, 127.9, 128.3, 128.5, 128.9, 130.3, 131.5, 133.2, 135.0, 135.2, 137.7, 143.3, 146.7, 149.8, 161.8, 161.3; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~31~H~21~Cl~2~N~3~O~2~Na, 560.0903; found, 560.0895.

### (*E*)-2-((1-Benzyl-5-methoxy-2-oxoindolin-3-ylidene)methyl)-3-(3-fluorobenzyl)quinazolin-4(3*H*)-one (**12ad**) {#sec4.2.30}

It was obtained as a reddish orange solid, yield 85%. *R*~f~ = 0.52 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.65 (s, 3H), 4.93 (s, 2H), 5.48 (s, 2H), 6.58 (d, *J* = 8.4 Hz, 1H), 6.77 (dd, *J*~1~ = 8.8 Hz, *J*~2~ = 2.4 Hz, 1H), 6.92 (td, *J*~1~ = 8.4 Hz, *J*~2~ = 2 Hz, 1H), 7.02 (dt, *J*~1~ = 9.6 Hz, *J*~2~ = 1.6 Hz, 1H), 7.12 (d, *J* = 8 Hz, 1H), 7.26--7.33 (m, 6H), 7.55 (s, 1H), 7.59 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.2 Hz, 1H), 7.79--7.82 (m, 2H), 7.84 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 1H), 8.42 (dd, *J*~1~ = 8 Hz, *J*~2~ = 1.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 43.9, 47.1, 55.7, 109.8, 113.3, 114.2, 114.4, 114.9, 115,2, 117.6, 120.6, 121.2, 122.8, 122.9, 125.1, 127.2, 127.4, 127.5, 127.7, 128.2, 128.8, 130.5, 130.6, 134.6, 135.0, 135.5, 138.0, 138.1, 138.7, 146.8, 150.4, 155.4, 161.8, 161.8, 164.3, 167.4; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~32~H~24~FN~3~O~3~Na, 540.1694; found, 540.1668.

### (*E*)-2-((1-Benzyl-5-methoxy-2-oxoindolin-3-ylidene)methyl)-3-(2-methoxybenzyl)quinazolin-4(3*H*)-one (**12ae**) {#sec4.2.31}

It was obtained as a reddish orange solid, yield 92%. *R*~f~ = 0.55 (TLC, Hex/EA, 1:1). ^1^H NMR (400 MHz, CDCl~3~): δ 3.63 (s, 3H), 3.86 (s, 3H), 4.91 (s, 2H), 5.49 (s, 2H), 6.56 (d, *J* = 8.4 Hz, 1H), 6.75 (dd, *J*~1~ = 8.4 Hz, *J*~2~ = 2.4 Hz, 1H), 6.81 (t, *J* = 7.6 Hz, 1H), 6.86 (d, *J* = 8 Hz, 1H), 7.09 (dd, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H), 7.19 (td, *J*~1~ = 8 Hz, *J*~2~ = 1.6 Hz, 1H), 7.29--7.32 (m, 4H), 7.56 (td, *J*~1~ = 7.6 Hz, *J*~2~ = 1.6 Hz, 2H), 7.74 (d, *J* = 2.8 Hz, 2H), 7.78 (d, *J* = 7.4, 1H), 7.81 (td, *J*~1~ = 7.4 Hz, *J*~2~ = 1.2 Hz, 1H), 8.40 (dd, *J*~1~ = 7.8 Hz, *J*~2~ = 1.2 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 42.9, 43.8, 55.4, 55.6, 109.6, 110.4, 112.9, 117.2, 120.7, 120.9, 120.9, 121.4, 123.5, 126.3, 126.3, 127.2, 127.4, 127.7, 127.9, 127.9, 128.8, 129.0, 134.0, 134.7, 135.6, 138.5, 146.8, 151.0, 155.3, 156.7, 161.9, 167.5; HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~33~H~27~N~3~O~4~, 552.1894; found, 552.1888.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b01514](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b01514).Green chemistry matrix calculation for compound **12a**; crystal data for **12a** and **12c**; and ^1^H NMR and ^13^C NMR spectra for all products ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01514/suppl_file/ao9b01514_si_001.pdf))
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